Participated · Seed · Nov 2025

Cordance Medical is building a noninvasive focused ultrasound system designed to temporarily and safely open the blood-brain barrier (BBB), enabling drugs and other therapeutic agents to reach the brain more effectively. The platform employs patient-specific signal processing with real-time monitoring of BBB opening and avoids the need for head fixation or live imaging, targeting practical outpatient use. While its first clinical application is brain cancer, the company envisions broader utility across multiple neurological conditions. Cordance has already secured FDA Breakthrough Device Designation in neuro-oncology and received a grant from the National Cancer Institute at the NIH to help fund its first-in-human U.S. trial. Proceeds from its recent seed financing will advance this clinical study and further product development. Based in Mountain View, California, the firm is supported by a strong syndicate of healthcare and neuro-oncology investors. The company has not disclosed revenue, user numbers, or other operating metrics.

Participated · Series A · Oct 2025

Trogenix is a biotechnology company focused on creating “one-and-done” treatments for aggressive solid tumours through its Odysseus platform. The platform combines genomics, oncology, immunotherapy and gene therapy, using AAV vectors to deliver proprietary Synthetic Super-Enhancers (SSEs) directly into tumour cells while evading immune detection. These SSEs precisely regulate gene expression to expose cancer cells to the immune system and trigger tumour cell death. If residual tumour cells persist, the approach acts as a ‘Trojan horse’ to counter recurrence. Founded by life-science investor 4BIO, the company aims to advance a pipeline of potentially curative therapies toward clinical trials. Trogenix is led by CEO Ken Macnamara and is headquartered in Edinburgh, Scotland. The new capital positions the company to accelerate pre-clinical research and move multiple candidates into the clinic.

Participated · Seed · Oct 2023

Modofi Bio specializes in direct DNA modification to develop therapeutics that target tumor-associated DNA repair defects. The company is based in New Haven, Connecticut, with offices and laboratories at the Elm City Bioscience Center near Yale. It raised an additional $4.3M in seed funding. Investors in this round included existing backers Connecticut Innovation, HighCape Capital, Advantage Capital (Ironwood), and the National Brain Tumor Society, plus new investors Pathway BioVentures, The Sontag Foundation, and BrightEdge (the impact investment arm of the American Cancer Society). Modofi Bio intends to use the funds to advance its lead molecules toward IND-enabling studies and phase I clinical trials. The company’s core approach is exploiting tumor-associated DNA repair defects through direct DNA modification. Modifi Biosciences develops small-molecule therapeutics that directly modify DNA to selectively target tumors with defects in DNA repair, notably loss of MGMT expression. The company’s core platform has been validated in vitro and in vivo in preclinical glioma and other cancer models, showing selective anti-tumor activity and a favorable therapeutic index. Modifi Bio’s lead approach targets cancers lacking MGMT, a defect present in substantial subsets of colon, small cell lung, and non-small cell lung cancers, suggesting broader applicability beyond brain tumors. Founders and scientific leadership include researchers from Yale, and the company is based at the Elm City Bioscience Center in New Haven. The team highlights that their molecules are structurally similar to previously FDA‑tested drugs but are designed to overcome resistance mechanisms. With recent non-dilutive funding and a completed seed round, the company is positioning its assets for IND‑enabling work and first clinical translation.

Participated · Series A · Nov 2021

Alpheus Medical develops a proprietary sonodynamic therapy platform that pairs Low‑Intensity Diffuse Ultrasound (LIDU™) with oral 5‑ALA, a tumor‑selective sensitizer, to deliver non‑thermal, tumor‑targeted treatment. The therapy is designed to be performed in an outpatient setting and to selectively destroy cancer cells across a brain hemisphere without the need for imaging or sedation. Early results from two studies in newly diagnosed and recurrent glioblastoma patients have shown promise. The company collaborates with global neuro‑oncology leaders and is supported by healthcare investors and nonprofit venture vehicles focused on cancer. Recent financing will fund a randomized Phase 2B controlled trial evaluating SDT’s efficacy in newly diagnosed glioblastoma. Alpheus is based in Chanhassen, Minnesota. Alpheus Medical is developing a non-invasive sonodynamic therapy (SDT) drug-device combination that uses a sonosensitizer activated by low-intensity ultrasound to selectively kill cancer cells. The lead product is designed for outpatient, repeatable whole-hemisphere treatment of recurrent high-grade gliomas, including rGBM, and eliminates the requirement for concomitant imaging. The therapy aims to address the heterogeneous and diffuse nature of glioblastoma by treating both the primary tumor site and diseased tissue throughout the hemisphere. The company reports the therapy is in early clinical stage use and is not yet commercially available. Alpheus has support from the American Cancer Society and the National Brain Tumor Society and is based in Oakdale, Minn. The recently closed financing will be used to advance a multi-site first-in-human trial evaluating safety, feasibility, and molecular and clinical effects.